<i>EFEMP1</i> as a Novel DNA Methylation Marker for Prostate Cancer: Array-Based DNA Methylation and Expression Profiling

Kim, Yong June; Yoon, Hyeun Joong; Kim, Seon‐Kyu; Kim, Young Won; Kim, Eun Jung; Kim, Isaac Yi; Kim, Wun-Jae

doi:10.1158/1078-0432.ccr-10-2817

Cited by 59 publications

(50 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fibulin-3 is expressed in condensing mesenchyme, giving rise to bony and cartilaginous structures (Zhang and Marmorstein, 2010). In previous studies, different types of cancer have been associated with fibulin-3, such as brain, hepatocellular, prostate, colorectal, and lung (Hu et al, 2009;Nomoto et al, 2010;Kim et al, 2011;Tong et al, 2011;Kim et al, 2012) however, there are few studies pertaining to the association with MM (Pass et al, 2012;Agha et al, 2014;Creaney et al, 2014). In these studies, levels of fibulin-3 investigated in patients with occupational asbestos exposure.…”

Section: Fibulin-3 As a Diagnostic Biomarker In Patients With Malignamentioning

confidence: 99%

Fibulin-3 as a Diagnostic Biomarker in Patients with Malignant Mesothelioma

Kaya

Demir²,

Taylan³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: New tumour biomarkers are being intensely investigated for malignant mesothelioma (MM). Fibulin-3 is produced in MM but its role remains uncertain. The aim of this study was to evaluate the validity of measuring serum fibulin-3 in the diagnosis and prognosis of MM. Materials and Methods: This prospective study was performed on 43 patients and 40 healthy controls who were admitted to our hospital between January 2012 and January 2014. Data from MM patients, including demographic and clinical features, routine laboratory data, levels of serum fibulin-3, and treatment outcomes were defined as potential prognostic factors. The receiver operating characteristic (ROC) curve for fibulin-3 was used to detect the cut-off value with highest sensitivity and specificity. Univariate survival analysis was performed using the Kaplan-Meier method in patients with MM. Afterwards, the possible factors identified with univariate analyses were entered into the cox regression analysis. Results: Our results revealed that patients with MM had significantly higher serum levels of fibulin-3 than controls. The results showed that the best cut-off point was 36.6 ng/ml with an AUC (area under the curve)=0.976, sensitivity=93.0% and specificity=90.0. In our study, the initial significant poor prognostic factors were advanced stage, high white blood cell count, high platelet count, high C-reactive protein (p<0.05 for each variable). Later, according to multivariate analysis the results showed only advanced stage as significant parameter (p=0.040). Conclusions: We determined that real use for serum fibulin-3 was not for prognosis but for diagnosis in MM. Also advanced stage was associated with poor MM prognosis.

show abstract

Section: Fibulin-3 As a Diagnostic Biomarker In Patients With Malignamentioning

confidence: 99%

Fibulin-3 as a Diagnostic Biomarker in Patients with Malignant Mesothelioma

Kaya

Demir²,

Taylan³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…FAM84A (NSE1) and SPOCK2 hypermethylation was the optimal biomarker combination in differentiating cancer from nonmalignant tissue (sensitivity, 80%; specificity, 95%; and accuracy, 96%; Chung et al 2008). Kim et al (2011d) combined genome wide DNA methylation and gene expression in pooled LNCaP-FGC, DU-145, and PC-3 cells compared with RWPE-1 non-malignant cultured prostate cells (Table 2). Three genes exhibited concordant methylation and expression changes, had a CpG island, and enhanced expression after 5-aza treatment.…”

Section: Genome Wide Dna Methylation In Prostate Cancermentioning

confidence: 99%

“…In clinical samples, EFEMP1 methylation was the optimal marker to differentiate prostate cancer from benign prostatic hyperplasia (sensitivity, 95.3% and specificity, 86.6%). EFEMP1 gene expression was also reduced in an independent prostate cancer cohort (Kim et al 2011d). Kron et al (2009) performed differential methylation hybridization (DMH) of prostate cancer samples (Table 2).…”

Section: Genome Wide Dna Methylation In Prostate Cancermentioning

confidence: 99%

Common gene pathways and families altered by DNA methylation in breast and prostate cancers

Day

Bianco‐Miotto²

2013

Endocrine-Related Cancer

View full text Add to dashboard Cite

Epigenetic modifications, such as DNA methylation, are widely studied in cancer as they are stable and easy to measure genome wide. DNA methylation changes have been used to differentiate benign from malignant tissue and to predict tumor recurrence or patient outcome. Multiple genome wide DNA methylation studies in breast and prostate cancers have identified genes that are differentially methylated in malignant tissue compared with non-malignant tissue or in association with hormone receptor status or tumor recurrence. Although this has identified potential biomarkers for diagnosis and prognosis, what is highlighted by reviewing these studies is the similarities between breast and prostate cancers. In particular, the gene families/pathways targeted by DNA methylation in breast and prostate cancers have significant overlap and include homeobox genes, zinc finger transcription factors, S100 calcium binding proteins, and potassium voltage-gated family members. Many of the gene pathways targeted by aberrant methylation in breast and prostate cancers are not targeted in other cancers, suggesting that some of these targets may be specific to hormonal cancers. Genome wide DNA methylation profiles in breast and prostate cancers will not only define more specific and sensitive biomarkers for cancer diagnosis and prognosis but also identify novel therapeutic targets, which may be direct targets of agents that reverse DNA methylation or which may target novel gene families that are themselves DNA methylation targets.

show abstract

“…Previous studies have reported that the EFEMP1 gene plays a role in several types of cancers, such as lung cancer, liver cancer, breast cancer, prostate cancer, and nasopharyngeal cancer (Yue et al, 2007;Sadr-Nabavi et al, 2009;Hwang et al, 2010;Nomoto et al, 2010;Kim et al, 2011;Zhang et al, 2011). Yue et al (2007) reported that alterations in the expression of EFEMP1 could inhibit lung cancer-cell growth, resulting in a high tumor grade.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, Nomoto et al (2010) reported that EFEMP1 was significantly down-regulated in tumor tissues, and that promoter methylation of the EFEMP1 gene could be a marker for the prognosis of hepatocellular carcinoma. Kim et al (2011) reported that epidermal EFEMP1 is a lead candidate methylation marker for prostate cancer and Zhang et al (2011) found that methylation of the EFEMP1 gene contributes to the pathogenesis of non-small cell lung cancer.…”

Section: Discussionmentioning

confidence: 99%

Assessing the association between EFEMP1 rs3791679 polymorphism and risk of glioma in a Chinese Han population

et al. 2016

View full text Add to dashboard Cite

ABSTRACT. In this study, we assessed the association between the EFEMP1 rs3791679 polymorphism and glioma risk in a Chinese Han population. A total of 94 glioma patients and 206 healthy controls who conformed to the inclusion and exclusion criteria were recruited from Baogang Hospital between March 2012 and October 2014. The EFEMP1 rs3791679 gene polymorphism was assessed using a polymerase chain reaction-restriction fragment length polymorphism assay and the results were statistically analyzed using SPSS Statistics 17.0. The results of unconditional logistic regression analysis revealed that the GG genotype of EFEMP1 rs3791679 was positively correlated with increased susceptibility to glioma (adjusted OR = 2.09, 95%CI = 1.21-7.81). Moreover, the GG genotype of EFEMP1 rs3791679 was correlated with higher risk of glioma compared to the AA+GA genotype (OR = 2.60, 95%CI = 1.08-6.28) in the regressive model. In conclusion, we report that the EFEMP1 rs3791679 polymorphism influences glioma susceptibility in the Chinese Han population.

show abstract

EFEMP1 as a Novel DNA Methylation Marker for Prostate Cancer: Array-Based DNA Methylation and Expression Profiling

Cited by 59 publications

References 31 publications

Fibulin-3 as a Diagnostic Biomarker in Patients with Malignant Mesothelioma

Fibulin-3 as a Diagnostic Biomarker in Patients with Malignant Mesothelioma

Common gene pathways and families altered by DNA methylation in breast and prostate cancers

Assessing the association between EFEMP1 rs3791679 polymorphism and risk of glioma in a Chinese Han population

Contact Info

Product

Resources

About